PRIMARY IMMUNE THROMBOCYTOPENIA: CURRENT ASPECTS OF DIAGNOSIS AND TREATMENT

Authors

  • Juraeva Nodira Tukhtapulatovna Author
  • Radjabova Selen Olimovna Author
  • Radjabova Komila Olimovna Author

Keywords:

thrombocytopenia, hemorrhagic syndrome, immune response, thrombopoietin, megakaryocytes.

Abstract

The aim of this paper is to present current approaches to the diagnosis and treatment of primary immune thrombocytopenia, including contemporary concepts of its pathogenesis, diagnostic criteria, assessment of bleeding risk, indications for initiating therapy, and the main approaches to pharmacological treatment. Particular attention is paid to modern therapeutic strategies for immune thrombocytopenia, including the use of thrombopoietin receptor agonists (TPO-RAs), which stimulate thrombopoiesis and increase platelet counts by acting on the megakaryocytic lineage of hematopoiesis.

References

1. Provan D., Arnold D.M., Bussel J.B. et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia 2019.

2. Neunert C., Terrell D.R., Arnold D.M. et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia 2019.

3. Cooper N., Kruse A., Kruse C. et al. Immune thrombocytopenia (ITP) world impact survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment 2021. Vol. 96, № 2. P. 188–198.

4.Matzdorff A., Alesci S.R., Gebhart J. et al. Expert report on immune thrombocytopenia: current diagnostics and treatment—recommendations from an expert group from Austria, Germany, and Switzerland 2023.

Published

2026-10-02